Who are Daivobet® gel's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): calcipotriene + clobetasol propionate, Calcipotriene and betamethasone dipropionate ointment, LEO 90105 = calcipotriol + betamethasone dipropionate, Calcipotriene/betamethasone gel and ointment.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/daivobet-gel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Daivobet® gel — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Daivobet® gel (Daivobet® gel) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topical combination therapy (vitamin D analog + corticosteroid). Area: Dermatology.

phase 3 Topical combination therapy (vitamin D analog + corticosteroid) Vitamin D receptor (VDR); glucocorticoid receptor (GR) Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Daivobet® gel (Daivobet® gel) — LEO Pharma. Daivobet combines calcipotriene (a vitamin D analog) and betamethasone dipropionate (a corticosteroid) to reduce inflammation and normalize skin cell differentiation in psoriasis.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Daivobet® gel TARGET	Daivobet® gel	LEO Pharma	phase 3	Topical combination therapy (vitamin D analog + corticosteroid)	Vitamin D receptor (VDR); glucocorticoid receptor (GR)
calcipotriene + clobetasol propionate	calcipotriene + clobetasol propionate	Leon Kircik, M.D.	marketed	Topical combination therapy (vitamin D analog + corticosteroid)	Vitamin D receptor (VDR) and glucocorticoid receptor (GR)
Calcipotriene and betamethasone dipropionate ointment	Calcipotriene and betamethasone dipropionate ointment	Galderma R&D	marketed	Topical combination therapy (vitamin D analog + corticosteroid)	Vitamin D receptor (VDR) and glucocorticoid receptor (GR)
LEO 90105 = calcipotriol + betamethasone dipropionate	LEO 90105 = calcipotriol + betamethasone dipropionate	LEO Pharma	phase 3	Topical combination therapy (vitamin D analog + corticosteroid)	Vitamin D receptor (VDR); glucocorticoid receptor (GR)
Calcipotriene/betamethasone gel and ointment	Calcipotriene/betamethasone gel and ointment	LEO Pharma	phase 3	Topical combination therapy (vitamin D analog + corticosteroid)	Vitamin D receptor (VDR); glucocorticoid receptor (GR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Topical combination therapy (vitamin D analog + corticosteroid) class)

LEO Pharma · 3 drugs in this class
Galderma R&D · 1 drug in this class
Leon Kircik, M.D. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Daivobet® gel — Competitive Intelligence Brief. https://druglandscape.com/ci/daivobet-gel. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing